Citius Oncology CTOR
NASDAQ CTOR
$0.56 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Citius Oncology (CTOR) Return on Sales [ROS] (2025 - 2026)

Updated

Citius Oncology (CTOR) recorded Return on Sales [ROS] of -583.54% in fiscal Q3 2026 (quarter ended Jun 30, 2026), up 1132.63 percentage points from the prior quarter.

Analysis

Citius Oncology (CTOR) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Citius Oncology 60.42 Mn 30.00 Mn 1.00 Mn -583.54%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -583.54%
Mar 31, 2026 -1,716.17%
Dec 31, 2025 -133.17%
API Access

Citius Oncology Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CTOR&period=max&api_key=YOUR_API_KEY